Cargando…
Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
(1) Shorter-duration dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy has been shown to significantly reduce bleeding events while preserving anti-ischemic effects in patients undergoing conventional percutaneous coronary interventions (PCI). Whether this strategy is also saf...
Autores principales: | Condello, Francesco, Sturla, Matteo, Terzi, Riccardo, Polimeni, Alberto, Stefanini, Giulio G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658113/ https://www.ncbi.nlm.nih.gov/pubmed/34884208 http://dx.doi.org/10.3390/jcm10235506 |
Ejemplares similares
-
Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020) -
Commentary: Ticagrelor monotherapy—Not for CABG?
por: Sandner, Sigrid, et al.
Publicado: (2022) -
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010) -
Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013) -
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial
por: Li, Pan, et al.
Publicado: (2016)